

## Cellular Transformation and Malignancy Induced by ras Require c-jun

RANDALL JOHNSON,<sup>1†</sup> BRUCE SPIEGELMAN,<sup>2</sup>  
DOUGLAS HANAHAN,<sup>1</sup> AND RON WISDOM<sup>3\*</sup>

*Hormone Research Institute and Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California 94143<sup>1</sup>; Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115<sup>2</sup>; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232<sup>3</sup>*

Received 8 March 1996/Returned for modification 24 April 1996/Accepted 2 May 1996

**ras is an important oncogene in experimental animals and humans. In addition, activated ras proteins are potent inducers of the transcription factor AP-1, which is composed of heterodimeric complexes of Fos and Jun proteins. Together with the fact that deregulated expression of some AP-1 proteins can cause neoplastic transformation, this finding suggests that AP-1 may function as a critical ras effector. We have tested this hypothesis directly by analyzing the response to activated ras in cells that harbor a null mutation in the c-jun gene. The transcriptional response of AP-1-responsive genes to activated ras is severely impaired in c-jun null fibroblasts. Compared with wild-type cells, the c-jun null cells lack many characteristics of ras transformation, including loss of contact inhibition, anchorage independence, and tumorigenicity in nude mice; these properties are restored by forced expression of c-jun. Rare tumorigenic variants of ras-expressing c-jun null fibroblasts do arise. Analysis of these variants reveals a consistent restoration of AP-1 activity. The results provide genetic evidence that c-jun is a crucial effector for transformation by activated ras proteins.**

Members of the ras family of GTPases, initially identified by virtue of their oncogenic potential, are involved in a number of biological processes. Signaling by ras proteins is critically dependent on the state of their guanine nucleotide, such that ras-GTP is active and ras-GDP is inactive. Regulation of the ras guanine nucleotide is complex, with both nucleotide exchange factors and GTPase-activating proteins playing important roles. These activities, in turn, are controlled by a variety of environmental stimuli, including peptide growth factors (for reviews, see references 8 and 10). The nature of the downstream targets of ras has only recently begun to be elucidated. The best-characterized target of ras signaling is the raf protein kinase, which participates in a mitogen-activated protein kinase (MAPK) cascade leading to activation of the ERK1 and ERK2 kinases (53, 54, 55, 60). ras is believed to have other possible effectors, including phosphatidylinositol 3'-OH kinase and the ral guanine nucleotide exchange factor (23, 30, 46, 51). In addition, ras appears to indirectly regulate a number of other candidate effectors, including the stress-activated protein kinase/Jun N-terminal kinase (SAPK/JNK), which phosphorylates and activates the c-jun N-terminal activation domain, and the rho family of GTPases, which regulate actin stress fiber assembly (16, 39, 44). Even less clear than the identities of the putative effectors are their relative roles in eliciting cellular responses. Genetic data strongly support a model in which activation of the raf protein kinase is critical for neoplastic transformation by ras. Mutant ras proteins that cannot interact with raf but can interact with other ras targets are incompetent for transformation (56). Activated raf kinase phosphorylates and activates MEK, which then activates MAPK. Constitutively active forms of raf and MEK also show transforming

activity, suggesting that activated MAPK is capable of eliciting biologic responses (13, 36).

Prominent among the nuclear targets of MAPK is the transcription factor AP-1. AP-1 is a sequence-specific DNA-binding transcription factor composed of a mixture of proteins encoded by the Fos and Jun family genes. AP-1 activity is induced by stimuli that activate MAPKs, including the ras GTPases and phorbol esters (3, 17). The mechanisms of AP-1 activation are only partially understood. Synthesis of *c-fos* mRNA is subject to control by the ternary complex proteins SAP1 and Elk1, both of which are believed to be direct targets for activation by MAPK (21, 37). Regulation of Jun proteins by MAPKs is less well understood, although agents that activate MAPKs, including growth factors and phorbol esters, also regulate the expression of *c-jun* mRNA and protein (32, 47). In addition, c-jun transcriptional activity is controlled by the phosphorylation of serines 63 and 73 by the SAPK/JNKs (43, 50). The extent to which this regulation of c-jun activity is under the control of ras is not yet clear.

The mixture of proteins that constitute AP-1 activity is both complex and dynamic, with the overall level of AP-1 activity and the abundance of specific family members changing under different conditions. Three observations have focused attention on the role of c-jun as a possible downstream effector for ras proteins. First, *c-jun* is oncogenic under certain conditions; second, *c-jun* activity is induced in response to ras activation; and third, overexpression of dominant negative *c-jun* alleles can inhibit transformation by ras proteins (1, 11, 18, 34, 39, 50). However, none of these observations directly address the issue of whether c-jun functions as a ras effector. In particular, the interpretation of experiments utilizing dominant negative Jun mutants is complicated by the fact these mutants are expected to interfere with the function of all Jun family members. Therefore, to directly test the hypothesis that c-jun is required for transformation by ras, we have analyzed the transforming response to ras in cells carrying a homozygous null mutation of

\* Corresponding author. Mailing address: Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232.

† Present address: Department of Biology, University of California, San Diego, San Diego, CA 92093.




FIG. 1. Wild-type and *c-jun* null cells immortalized by SV40 T Ag show similar growth rates. (A) *c-jun*<sup>+/+</sup> (squares) and *c-jun*<sup>-/-</sup> (diamonds) cells were immortalized by expression of SV40 T Ag. The resulting cell lines were plated in DMEM with 10% FCS at 10<sup>3</sup> cells per 6-cm-diameter dish, and cell numbers were counted every 24 h. (B) The characteristics of expression of T Ag in the two cell lines were compared by Western blotting using a monoclonal antibody specific for T Ag. Sizes are indicated in kilodaltons.

the *c-jun* gene. We find that these cells are markedly impaired both in the AP-1 transcriptional response and in the ability to be transformed by activated ras proteins. Rare variants of *c-jun* null cells that are transformed in a ras-dependent manner do arise; analysis of these variants demonstrates that they all show increased AP-1 DNA binding activity compared with the non-transformed parent. Taken together, the results provide clear genetic evidence that *c-jun* and AP-1 are essential for transformation by ras proteins.

#### MATERIALS AND METHODS

**Cells and viruses.** Primary embryo fibroblasts (28) were isolated from 11.5-day-old mouse embryos by previously published methods. Wild-type and *c-jun* null cells were transfected with plasmid pOT, which directs expression of the simian virus 40 (SV40) large T antigen (T Ag), and immortalized cell lines were derived. cDNAs encoding H-ras 61L, *c-jun*, *c-jun* ΔLZ, JunB, or JunD were cloned into the pBabe series of retroviral vectors (40). *c-jun* ΔLZ contains a deletion of three amino acids (284 to 286) in the leucine zipper and is defective for both dimerization and DNA binding. H-ras 61L (a gift from C. Der) was cloned into pBabe-puro, which allows for selection in puromycin. All of the Jun family proteins were cloned into pBabe-Hygro, which allows for selection in hygromycin. Proviral DNAs were transfected into ψ-2 cells, and stably transfected cells were isolated. Supernatants from these cells were then used to infect the T Ag-derived cell lines. Selection used 3 μg of puromycin per ml and 200 μg of hygromycin per ml. Cell genotypes were confirmed by Southern blotting. Cell photomicrographs were taken on a Zeiss Axiovert microscope.

**Gel shift analysis.** Nuclear extracts were prepared by previously described methods (2). Gel shift experiments typically used 5 μg of nuclear extract in buffer C (20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid] [pH 7.9], 420 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 0.5 mM dithiothreitol, 25% glycerol), 3 μg of poly(dI-dC), and a <sup>32</sup>P-labeled double-stranded oligonucleotide corresponding to the human collagenase AP-1 site (top strand, 5' AGCTT GTGAGTCAGCCGGAT 3'). Samples were incubated at room temperature for 20 min and then run on 4% polyacrylamide gels in 0.5% Tris-borate-EDTA. Control experiments used an Oct-1 probe to verify that equal amounts of Oct-1 DNA binding activity were present.

**Protein and RNA analysis.** Jun proteins were detected by Western blotting (immunoblotting) of nuclear extracts. Extracts were prepared as described above, and 30 μg of nuclear extract per sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Samples were blotted onto nylon membranes and probed with an antiserum against *c-jun*, JunB, or JunD (JunB and JunD antibodies were a generous gift of Rodrigo Bravo). SV40 T Ag was detected by immunoblotting of nuclear extracts with the monoclonal antibody KT3. Detection was by chemiluminescence. ras proteins were immunoprecipitated from cells metabolically labeled with <sup>35</sup>S-amino acids by using the ras-specific monoclonal antibody Y259. The immunoprecipitates were then separated by SDS-PAGE and visualized by fluorography.

RNA isolation and Northern (RNA) blotting were performed as previously

described (5, 58). Stromelysin mRNA was detected by using a <sup>32</sup>P-radiolabeled cDNA fragment from the mouse stromelysin cDNA (a generous gift from Lynn Matrisian).

**Transformation assays.** Saturation density was measured by plating 4 × 10<sup>5</sup> cells in 6-cm-diameter dishes in Dulbecco's minimal essential medium (DMEM) with 10% fetal calf serum (FCS). Twelve hours after plating, the medium was replaced with DMEM supplemented with 0.5, 2, or 5% FCS. After an additional 4 days, the cell number was determined by counting. For each cell type, the saturation density was determined in triplicate at least twice.

Soft-agar colony assays were carried out by seeding 2 × 10<sup>4</sup> cells in soft agar (0.4% agar in DMEM with 5% FCS). Dishes were fed twice per week, and macroscopic colonies were counted after 14 days. For ras-expressing *c-jun*<sup>+/+</sup> cells, which have a high cloning efficiency in soft agar, cells were also plated at 2 × 10<sup>3</sup> and 500 cells per plate.

For tumorigenicity assays, nude mice were injected with 10<sup>7</sup> cells in phosphate-buffered saline subcutaneously. The mice were monitored twice weekly for the appearance of tumors.

#### RESULTS

The availability of mice harboring targeted disruptions of the *c-jun* gene provided an opportunity to examine the role of *c-jun* in transformation by ras. Mutation of the *c-jun* gene results in embryonic lethality; in addition, fibroblasts isolated from *c-jun*<sup>-/-</sup> embryos grow poorly in culture, and despite many attempts, we have not succeeded in generating 3T3-like cell lines from *c-jun* null cells (19, 28, 57). To study the biochemical and biologic responses to ras, immortalized cell lines were generated by expression of SV40 T Ag (see Materials and Methods). Matched fibroblast cell lines derived from wild-type and *c-jun* null cells were characterized. These cell lines do not senesce; they express equivalent levels of T Ag, grow at the same rate (Fig. 1), and are similar in appearance morphologically (see Fig. 3a). In addition, they are not transformed, as measured by several different criteria (see below), consistent with previously published data showing that expression of T Ag in primary embryo fibroblasts results in efficient immortalization but not cellular transformation (4, 27, 41). These cell lines are therefore suitable host cells in which to assay the cellular response to ras. All of the experiments described below were carried out in these T Ag-immortalized cell lines.

**Transformation by ras requires c-jun.** Wild-type and *c-jun* null fibroblasts were infected with a recombinant retrovirus directing expression of an activated *ras* allele (H-ras 61L). Pools of infected cells were isolated and analyzed for expression of activated ras protein by immunoprecipitation from metabolically labeled cells. Activated ras proteins were expressed at equivalent levels in *c-jun*<sup>+/+</sup> and *c-jun*<sup>-/-</sup> cells (Fig. 2A).

ras-expressing *c-jun*<sup>+/+</sup> and *c-jun*<sup>-/-</sup> cells were analyzed for biochemical evidence of AP-1 activation. Expression of activated ras proteins resulted in approximately a fivefold induction of *c-jun* protein in wild-type cells, as measured by Western blotting, while no *c-jun* protein was detected in *c-jun*<sup>-/-</sup> cells (Fig. 2B); this result is similar to the induction of *c-jun* protein that is observed in 3T3 fibroblasts following transformation by ras (42). The induction of *c-jun* protein was accompanied by an increased level of AP-1 DNA binding activity in ras-expressing wild-type cells, while AP-1 DNA binding activity was only slightly induced in ras-expressing *c-jun*<sup>-/-</sup> cells (Fig. 2C). This increase in AP-1 DNA binding activity was translated into an increase in expression of the stromelysin gene, a known AP-1-responsive gene (Fig. 2D) (38). Taken together, these data indicate that *c-jun* expression is required for activation of the AP-1 response by ras in fibroblasts. Additionally, they suggest that *c-jun* is the Jun family protein responsible for the increased AP-1 DNA binding activity that is observed in response to activated ras.

Having demonstrated that the AP-1 response to activated ras was markedly attenuated in *c-jun*<sup>-/-</sup> cells, we analyzed




FIG. 2. *c-jun* expression is required for AP-1 activation by ras. (A) *c-jun*<sup>+/+</sup> and *c-jun*<sup>-/-</sup> cells were infected with a recombinant retrovirus directing expression of H-ras 61L. Cells of the indicated genotypes, either expressing or not expressing activated ras, were metabolically labeled with <sup>35</sup>S-labeled amino acids, and ras proteins were immunoprecipitated with a monoclonal antibody to ras proteins. The top band represents the endogenous wild-type cellular ras proteins, while the more rapidly migrating species (arrowhead) represents activated ras protein. Sizes are indicated in kilodaltons. (B) Nuclear extracts from cells of the indicated genotypes were analyzed for the expression of c-jun protein by Western blotting. Sizes are indicated in kilodaltons. (C) The same cell types were analyzed for total AP-1 DNA binding activity by gel shift analysis. Nuclear extracts were prepared from each cell type and incubated with a <sup>32</sup>P-labeled probe corresponding to the human collagenase AP-1 site. The samples were separated by electrophoresis on 4% polyacrylamide gels in 0.5% Tris-borate-EDTA. (D) The same cell types were analyzed by Northern blotting for expression of stromelysin mRNA (top panel) or glyceraldehyde-3-phosphate dehydrogenase as a loading control (lower panel).

several parameters related to the transformed phenotype. ras-expressing *c-jun*<sup>+/+</sup> cells, in contrast to ras-expressing *c-jun*<sup>-/-</sup> cells or cells not expressing activated ras, showed a typical transformed phenotype, with a refractile and rounded appearance (Fig. 3a). The ras-expressing wild-type cells had undergone a loss of contact inhibition, as measured by cell density at saturation of the culture (Fig. 3b and Table 1); this loss of contact inhibition required both activated ras expression and *c-jun* expression, as it was not observed in cells with other genotypes. The same cells were tested for loss of anchorage dependence by growth in soft agar. Once again, ras-expressing *c-jun*<sup>+/+</sup> cells, but not other cells, formed colonies in soft agar (Table 1). Finally, we tested the ability of these cells to form tumors after subcutaneous injection into nude mice. All animals injected with ras-expressing *c-jun*<sup>+/+</sup> cells developed tumors by 10 days after injection, while tumors were not evident in animals injected with other cell types (Fig. 3c and Table 1). At later time points (14 to 16 weeks), animals injected with *c-jun*<sup>-/-</sup> cells developed tumors in a ras-dependent manner (see below). Thus, by four different criteria, i.e., morphology, loss of contact inhibition, anchorage-independent growth, and tumorigenesis, neoplastic transformation by ras requires *c-jun* expression.

**Rescue of transformation in *c-jun*<sup>-/-</sup> cells by *c-jun*.** If *c-jun*<sup>-/-</sup> cells are not transformed in response to expression of activated ras solely as a result of loss of *c-jun* expression, then it should be possible to transform these cells by expression of

*c-jun*. To test this hypothesis, ras-expressing *c-jun* null cells were infected with a retrovirus directing expression of *c-jun*. Western blotting confirmed that *c-jun* protein was expressed at levels approximating those of ras-expressing *c-jun*<sup>+/+</sup> cells (data not shown). The expression of *c-jun* in ras-expressing *c-jun*<sup>-/-</sup> cells resulted in an induction in stromelysin expression to levels similar to those seen in ras-expressing *c-jun*<sup>+/+</sup> cells (data not shown), demonstrating that the diminution in stromelysin expression in ras-expressing *c-jun* null cells was due to the absence of *c-jun*. These cells showed morphologic changes similar to those of ras-expressing *c-jun*<sup>+/+</sup> cells and displayed an increased saturation density, demonstrating loss of contact inhibition (Fig. 3a and Table 1). *c-jun*<sup>-/-</sup> ras-*c-jun*-expressing cells formed soft-agar colonies much more efficiently than the *c-jun*<sup>-/-</sup> ras-expressing parent cells (Table 1). When injected into nude mice, the *c-jun*<sup>-/-</sup> cells expressing ras and ectopic *c-jun* formed progressively growing tumors at 2 weeks, while the *c-jun*<sup>-/-</sup> ras-expressing parent cells did not (Table 1). Thus, all of the phenotypes produced by expression of activated ras protein in *c-jun*<sup>+/+</sup>, but not *c-jun*<sup>-/-</sup>, cells were efficiently rescued by expression of recombinant *c-jun* in *c-jun* null cells. This rescue required active *c-jun* protein; expression of a *c-jun* mutant protein incapable of dimerization or DNA binding did not rescue any of the phenotypes described above (Fig. 3a and Table 1). In addition, transformation required the expression of activated ras, as expression of *c-jun*<sup>+/+</sup> or *c-jun*<sup>-/-</sup> cells did not result in transformation (Table 1). These data demonstrate that loss of *c-jun* protein is in fact the cause of the defective ras response in *c-jun* null cells. Furthermore, forced expression of *c-jun* in the absence of activated ras did not induce transformation, suggesting that induction of *c-jun* is not the sole mechanism by which ras proteins function.

The ability of exogenously expressed *c-jun* protein to rescue ras responsiveness provides a novel assay for the analysis of Jun function. The data in Fig. 2 suggest that *c-jun* is the sole Jun family member that is induced in response to expression of activated ras in these cells. Analysis of the expression of *junB* and *junD* mRNAs and proteins confirmed that they are expressed at the same levels in the presence or absence of activated ras (data not shown). This finding suggested the possibility that ectopic expression of either JunB or JunD might rescue the ras response in *c-jun*<sup>-/-</sup> cells. To test this idea directly, ras-expressing *c-jun*<sup>-/-</sup> cells were infected with recombinant retroviruses directing expression of either JunB or JunD and analyzed as described above. Both JunB and JunD rescue transformation by ras in *c-jun*<sup>-/-</sup> cells, although the efficiency of rescue is reduced compared with that of *c-jun* (Table 1). In addition, we observed that there is not complete correlation between all of the assays used to measure transformation. For example, JunD inefficiently restores soft-agar colony formation but efficiently rescues tumorigenicity (Table 1). The basis of this incomplete rescue is not clear.

***c-jun*<sup>-/-</sup> cells generate tumorigenic variants.** In the experiments described above, *c-jun*<sup>-/-</sup> cells expressing activated ras failed to generate tumors at 2 weeks, while ras-expressing *c-jun*<sup>+/+</sup> cells generated rapidly growing tumors at this time (Fig. 3). At later time points (14 to 16 weeks), however, animals injected with ras-expressing *c-jun*<sup>-/-</sup> cells developed progressively enlarging tumors. These tumors arose in a ras-dependent manner, as they were not observed in animals injected with cells not expressing ras or in *c-jun*<sup>-/-</sup> cells expressing exogenous *c-jun*. The tumors were dissected, and cells were isolated and propagated in culture; upon reinjection into animals, these cells were rapidly tumorigenic. Molecular analysis confirmed that the tumorigenic cells were composed of *c-jun*<sup>-/-</sup> cells. Southern blotting demonstrated that each of the




FIG. 3. Transformation by ras requires c-jun expression. (A) Phase-contrast photomicrographs of cells expressing the indicated genes. (B) Fibroblasts expressing the indicated genes were seeded at  $4 \times 10^5$  cells per 6-cm-diameter dish. After 12 h, the medium was changed to DMEM with 5% FCS (black bars), 2% FCS (white bars), or 0.5% FCS (hatched bars). Cells were counted after growth for an additional 4 days. Each experiment was carried out in triplicate at least twice. (C) Cells of the indicated genotypes were injected subcutaneously into nude mice ( $10^7$  cells per animal). The photographs were taken 2 weeks after injection.

tumors was composed of cells containing a single ras provirus; however, the site of integration was different in each of the tumors (data not shown). Therefore, these tumors represent four independent events.

The tumorigenic variants of ras-expressing *c-jun*<sup>-/-</sup> cells were analyzed for other aspects of the transformed phenotype. All of these cell lines showed altered morphology (Fig. 4). In addition, they showed loss of contact inhibition, and three of

the four grew efficiently in soft agar (Table 2). Therefore, these cells are phenotypically similar to ras-expressing *c-jun*<sup>+/+</sup> cells.

Tumorigenic variants of ras-expressing *c-jun* null cells could arise by two possible mechanisms. One mechanism would involve the activation of AP-1 activity in a c-jun-independent manner. Alternatively, these cells could have arisen by a bypass mechanism, in which AP-1 activity does not contribute to the transformed state of the cells. It should be possible to distin-

TABLE 1. Characteristics of *c-jun* cells

<i>c-jun</i> genotype	Exogenous genes	Saturation density <sup>a</sup> (10 <sup>6</sup> )	Soft-agar colonies <sup>b</sup>	No. of nude mice with tumors <sup>c</sup>
+/+		2.6	0	0
+/+	<i>ras</i>	9.4	1,400 <sup>d</sup>	4
-/-		2.4	0	0
-/-	<i>ras</i>	3.3	1	0
+/+	<i>c-jun</i>	3.1	0	0
-/-	<i>c-jun</i>	2.7	0	0
-/-	<i>ras</i> + <i>c-jun</i>	8.2	458	4
-/-	<i>ras</i> + <i>c-jun</i> ΔLZ	3.7	0	0
-/-	<i>ras</i> + <i>junB</i>	6.8	126	4
-/-	<i>ras</i> + <i>junD</i>	5.1	7	4

<sup>a</sup> Cells were plated at  $4 \times 10^5$ /6-cm-diameter dish in DMEM with 10% FCS. Twelve hours after plating, the medium was changed to DMEM with 2% FCS, and cells were counted after an additional 4 days.

<sup>b</sup> Cells ( $2 \times 10^4$ ) were plated in soft agar as described in Materials and Methods. Macroscopic colonies were counted after 14 days.

<sup>c</sup> Cells ( $10^7$ ) suspended in phosphate-buffered saline were injected subcutaneously into nude mice, which were then monitored for the appearance of tumors. Each group contained four mice.

<sup>d</sup> The high soft-agar colony formation rate of these cells made it difficult to count colonies after plating of  $2 \times 10^4$  cells. Therefore, these cells were also plated at  $2 \times 10^3$  and 500 cells per dish to determine soft-agar colony-forming efficiency.

guish between these different mechanisms by analyzing the AP-1 status of these cells. We therefore analyzed the AP-1 DNA binding activity present in nuclear extracts of these cells. The results showed that in all cases, the level of AP-1 DNA binding activity was higher than that in the nontumorigenic parental cells, although in all cases it was less than that observed in *ras*-expressing *c-jun*<sup>+/+</sup> cells (Fig. 5a). Western blotting demonstrated that in each case, the amounts of JunB protein present in the nuclear extract were similar in the nontumorigenic *c-jun*<sup>-/-</sup> *ras*-expressing cells and in the tumorigenic variants. In contrast, each of these variants showed an increase in JunD protein compared with the nontumorigenic parent (Fig. 5b). These results suggest that in the absence of *c-jun*, increased expression of JunD protein may contribute to *ras*-dependent transformation. The mechanism by which JunD

is induced in the tumorigenic variants is not clear. The nontumorigenic parental cells and the tumorigenic variants express equivalent levels of *junD* mRNA (data not shown), and therefore the induction of JunD protein that is observed does not occur at the transcriptional level. Whether induction occurs by translational control or by a posttranslational mechanism involving altered rates of protein turnover remains to be determined. These experiments demonstrate that even in the absence of *c-jun* protein, induction of AP-1 activity is correlated with transformation by *ras*.

## DISCUSSION

We have used fibroblasts immortalized by SV40 T Ag to assess the role of *c-jun* in the transforming response to *ras*. T Ag-immortalized *c-jun*<sup>-/-</sup> cells showed a defective *ras* response compared with their *c-jun*<sup>+/+</sup> counterparts. That this defect in oncogenic signaling is due to selective loss of *c-jun* is demonstrated by the rescue by ectopic expression of *c-jun*. Our ability to isolate rare transformed variants from *c-jun*<sup>-/-</sup> cells shows that in every case, bypass involves an increase in AP-1 activity. Thus, several different lines of evidence converge to demonstrate an important role for AP-1 in transformation by *ras* proteins.

***c-jun* and the cell cycle.** Fibroblasts isolated from *c-jun* null embryos fail to grow in culture. When *c-jun*<sup>-/-</sup> cells are treated with growth factor, the cells fail to divide and are blocked in the G<sub>1</sub> phase of the cell cycle (28). As induction of AP-1 activity is implicated in the mitogenic response to growth factors, this growth defect presumably represents an inability to synthesize a component critical for cell cycle progression. The ability of SV40 T Ag to bypass the growth requirement for *c-jun* expression may provide some insight into the mechanism of the cell cycle arrest in *c-jun* null cells and the role of AP-1 proteins in cell cycle progression in response to growth factors. T Ag possesses a number of biochemical activities, including the ability to bind to and functionally inactivate pRb and p53 (15, 33), both of which are capable of mediating G<sub>1</sub> arrest. Further experiments may help to clarify the mechanism of the cell cycle arrest in *c-jun*<sup>-/-</sup> cells.




FIG. 4. Morphologies of tumorigenic variants of *ras*-expressing *c-jun*<sup>-/-</sup> cells. Animals injected with *ras*-expressing *c-jun*<sup>-/-</sup> cells developed tumors after 14 to 16 weeks. The tumors were dissected, and cells were plated in culture. Phase-contrast photomicrographs of the tumorigenic cells are shown.

TABLE 2. Characteristics of variants of ras-expressing *c-jun* cells

<i>c-jun</i> genotype	Saturation density <sup>a</sup> (10 <sup>6</sup> )	Soft-agar colonies <sup>b</sup>	No. of nude mice with tumors <sup>c</sup>
+/+ ras	10.3	31	4/4
-/- ras	3.2	0	0/4
Variants			
1	11.7	22	1/1
2	12.4	29	1/1
3	6.8	1	1/1
4	9.5	37	1/1

<sup>a</sup> Cells were plated at  $4 \times 10^5$ /6-cm-diameter dish in DMEM with 10% FCS. Twelve hours after plating, the medium was changed to DMEM with 2% FCS, and cells were counted after an additional 4 days.

<sup>b</sup> Cells (500) were plated in soft agar as described in Materials and Methods. Macroscopic colonies were counted after 14 days. For variant 3, plating  $2 \times 10^4$  cells resulted in 46 colonies, a result that can be compared with those shown in Table 1.

<sup>c</sup> Cells (10<sup>7</sup>) suspended in phosphate-buffered saline were injected subcutaneously into nude mice, which were then monitored for the appearance of tumors.

**c-jun as an oncogenic effector.** Members of the ras family of GTPases are implicated in formation of many different tumor types. The precise mechanisms of transformation by ras proteins remain unclear, but several pieces of evidence suggest that AP-1 is an important downstream ras effector. These include the observations that AP-1 activity is induced by ras, that activating mutations in some AP-1 family members are oncogenic, and that expression of dominant negative *c-jun* alleles inhibits transformation by ras (1, 11, 14, 16, 18, 34). We have provided direct genetic evidence that efficient transformation by activated ras proteins requires c-jun. In addition, we have shown that the rare transformed variants that do arise in *c-jun* null cells show increased AP-1 activity. Taken together, these data strongly suggest that AP-1 activity is crucial for transformation by the ras GTPases.

Transcriptional control and oncogenic potential for c-jun are most clearly demonstrated in the context of AP-1 activity. However, c-jun has also been shown to interact with a number of other transcription factors, including the glucocorticoid receptor, the myogenic proteins, and the CREB family member ATF-2 (6, 17, 26, 29, 35, 49, 59). It is possible that transformation by c-jun is a result of modulation of the activity of one or more of these transcription factors. Whatever the precise mechanism, the results provide genetic evidence that c-jun is a critical ras effector.

Our data can be compared with those of studies evaluating the role of c-fos in neoplastic transformation by ras proteins. Recent data demonstrate a crucial role for c-fos in the progression of skin cancer in animals induced by a combination of an activated *ras* transgene and topical application of phorbol esters (48). However, experiments similar to those described here show that c-fos expression is not required for ras transformation of fibroblasts (24). This finding suggests that there may be some cell type variability in the requirements for specific AP-1 proteins, perhaps reflecting cell type differences in expression of other AP-1 family members. It will therefore be important to evaluate the role of c-jun in oncogenic transformation by ras proteins in a different cellular context.

In addition to ras, several other oncogenic signaling molecules, including the growth factor receptor tyrosine kinases, the src family of cytoplasmic tyrosine kinases, and the raf serine/threonine kinase, activate AP-1 activity. Whether transformation by these molecules requires c-jun remains to be demonstrated. *c-jun*<sup>-/-</sup> embryonic stem cells grow poorly as teratocarcinomas, suggesting that c-jun is an important onco-

genic effector for the growth of these tumors (20). Likewise, a role for AP-1 proteins as effectors in normal physiologic signaling by ras proteins remains to be demonstrated, although expression of dominant negative Jun mutants in *Drosophila melanogaster* suggests that Jun does play a role in signaling by the sevenless tyrosine kinase and ras proteins (9).

**AP-1 regulation by ras proteins.** AP-1 apparently receives multiple ras-dependent signals. Activation of the MAPK/ERK pathway by ras most clearly influences AP-1 activity by increasing the expression of the Fos family proteins (21, 37). Essentially all of the AP-1 DNA binding activity present in our ras-transformed cells is sensitive to treatment with an antibody that recognizes the Fos family proteins (data not shown), demonstrating that the AP-1 activity in these cells is composed exclusively of Fos-Jun heterodimers and not Jun-Jun homodimers. As Fos proteins contribute to AP-1 DNA binding activity only as part of a Fos-Jun complex, ras signaling through Fos proteins is expected to be dependent on the expression of Jun proteins. It is not clear if MAPK/ERK signals directly regulate the expression or activity of Jun family proteins, although many activators of the MAPK/ERKs do activate c-jun (32, 47).

The Jun family of proteins are also regulated by phosphorylation of serine residues in their activation domains by the SAPK/JNKs (43, 50). In some, but not all, cell types, these kinases can be activated by ras signaling (7, 31, 39, 50). Analysis of the ability of a c-jun mutant protein containing alanine substitutions at residues 63 and 73 shows that it efficiently rescues soft-agar colony formation and high saturation density but not tumorigenicity (data not shown). We have not yet determined the phosphorylation state of serines 63 and 73 or the activity of SAPK/JNK in this system, which may provide insight into the ability of ras proteins to regulate this signaling pathway. In any event, our results provide clear genetic evidence that c-jun is a crucial component of ras signaling through AP-1. Also unclear is the potential regulation of AP-1 by other potential ras effectors, including phosphatidylinositol 3'-OH kinase, fos-regulating kinase (FRK), and the ral GTPase.

**JunD as a possible oncogenic effector.** The Jun family of proteins consists of c-jun, JunB, and JunD. Previous functional studies have suggested that JunD may function as a negative regulator of AP-1 activity and impair transformation by ras proteins (42). Our data suggest that JunD efficiently rescues tumorigenicity, but not soft-agar colony formation, by ras-expressing *c-jun*<sup>-/-</sup> cells. In addition, the analysis of tumorigenic *c-jun*<sup>-/-</sup> variants shows a consistent increase in JunD protein levels. These data suggest that JunD can contribute to positive regulation of AP-1 activity. The reasons for this discrepancy




FIG. 5. Tumorigenic variants of ras-expressing *c-jun*<sup>-/-</sup> cells show increased AP-1 DNA binding activity. (A) Nuclear extracts were prepared from cells of each of the indicated genotypes and analyzed by gel shift for AP-1 DNA binding activity, using a probe corresponding to the collagenase AP-1 site. (B) The same extracts were analyzed for the expression of JunB and JunD proteins by Western blotting.

are not immediately apparent, but data from several other cell types support the idea that JunD can function either as a positive regulator or as a negative regulator of AP-1 signaling (12, 22, 52). These data suggest that the role of JunD may be dependent on the cell context, with the levels of other AP-1 family proteins perhaps contributing to some of the differences observed.

The mechanism by which JunD expression is induced in *c-jun* null tumorigenic cells is unclear. Northern blotting demonstrates that there is no change in mRNA levels, and so the increase in JunD protein presumably occurs at either a translational or a posttranslational level. Further experiments may provide some insight into this potentially novel mechanism of control of AP-1 activity.

#### ACKNOWLEDGMENTS

We thank Rodrigo Bravo for generously providing the JunB and JunD antisera, Charles Albright for providing the ras monoclonal antibody Y259 and the T-Ag monoclonal antibody KT3, Channing Der for providing the human H-ras 61L cDNA, and Lynn Matrisian for providing the mouse stromelysin cDNA. We thank Phillip Galante and Connie Moore for technical support. We thank Erwin Wagner and Michael Karin for critically reviewing the manuscript.

R.J. was the recipient of a Jane Coffin Childs Cancer Research Fellowship. This work was supported by grants from the NIH to B.S., D.H., and R.W. and an American Cancer Society Junior Faculty Award to R.W.

#### REFERENCES

- Alani, R., P. Brown, H. Binetruy, R. K. Dosaka, P. Rosenberg, P. Angel, M. Karin, and M. J. Birrer. 1991. The transactivating function of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. *Mol. Cell. Biol.* **11**:6286–6295.
- Andrews, N. C., and D. V. Faller. 1991. A rapid micropreparation technique for the extraction of DNA-binding proteins from limiting numbers of mammalian cells. *Nucleic Acids Res.* **19**:2459.
- Angel, P., M. Imagawa, R. Chiu, B. Stein, R. J. Imbra, H. J. Rahmsdorf, C. Jonat, P. Herrlich, and M. Karin. 1987. Phorbol-ester inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. *Cell* **49**:729–739.
- Assin, C., and M. Bastin. 1985. Sequences from polyoma virus and simian virus 40 large T genes capable of immortalizing primary rat embryo fibroblasts. *J. Virol.* **56**:958–968.
- Auffray, C., and H. Rougeoun. 1980. Purification of mouse immunoglobulin heavy chain messenger RNAs from total myeloma tumor RNA. *Eur. J. Biochem.* **107**:303–314.
- Bengal, E., L. Ransone, R. Scharfmann, V. J. Dwarki, S. Tapscott, H. Weintraub, and I. M. Verma. 1992. Functional antagonism between c-Jun and MyoD proteins: a direct physical association. *Cell* **68**:507–519.
- Binetruy, B., T. Smeal, and M. Karin. 1991. Ha-ras augments c-jun activity and stimulates phosphorylation of its transactivation domain. *Nature (London)* **351**:122–127.
- Boguski, M. S., and F. C. McCormick. 1993. Proteins regulating ras and its relatives. *Nature (London)* **366**:343–354.
- Bohmann, D., M. C. Ellis, L. M. Staszewski, and M. Mlodzik. 1994. Drosophila jun mediates ras-dependent photoreceptor determination. *Cell* **78**:973–986.
- Bokuch, G. M., and C. J. Der. 1993. Emerging concepts in the ras superfamily of GTP-binding proteins. *FASEB J.* **7**:750–759.
- Bos, T. J., F. Monteclaro, F. Mitsunobu, A. R. Ball, Jr., C. H. W. Chang, T. Nishimura, and P. K. Vogt. 1990. Efficient transformation of chicken embryo fibroblasts by c-jun requires structural modification in coding and non-coding sequences. *Genes Dev.* **4**:1677–1687.
- Bossy-Wetzel, E., R. Bravo, and D. Hanahan. 1992. Transcription factors JunB and c-Jun are selectively up-regulated and functionally implicated in fibrosarcoma development. *Genes Dev.* **6**:2340–2351.
- Cowley, S., H. Paterson, P. Kemp, and C. J. Marshall. 1994. Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. *Nature (London)* **356**:77–79.
- Curran, T., G. Peters, C. Van Beveren, N. M. Teich, and I. M. Verma. 1982. FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. *J. Virol.* **44**:674–682.
- DeCaprio, J. A., J. W. Ludlow, J. Figge, J.-Y. Shew, C.-M. Huang, W.-H. Lee, E. Marsilio, E. Paucha, and D. M. Livingston. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. *Cell* **54**:275–283.
- Derijard, B., M. Hibi, I. Wu, T. Barrett, B. Su, T. Deng, M. Karin, and R. J. Davis. 1994. JNK1: a protein kinase stimulated by UV light and Ha-ras that binds and phosphorylates the c-jun activation domain. *Cell* **76**:1025–1035.
- Diamond, M. L., J. N. Miner, S. K. Yoshinaga, and K. R. Yamamoto. 1990. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. *Science* **249**:1266–1272.
- Gutman, A., and B. Wasylyk. 1990. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA-3 and AP-1 binding sites. *EMBO J.* **9**:2241–2246.
- Hilberg, F., A. Aguzzi, N. Howells, and E. F. Wagner. 1993. c-jun is essential for normal mouse development and hepatogenesis. *Nature (London)* **365**:179–181.
- Hilberg, F., and E. F. Wagner. 1992. Embryonic stem (ES) cells lacking functional c-jun: consequences for growth and differentiation, AP-1 activity, and tumorigenicity. *Oncogene* **7**:2371–2380.
- Hill, C. S., R. Marais, S. John, J. Wynne, S. Dalton, and R. Treisman. 1993. Functional analysis of a growth factor-responsive transcription factor complex. *Cell* **73**:395–406.
- Hirai, S., R. P. Ryseck, F. Mehta, R. Bravo, and M. Yaniv. 1989. Characterization of JunD: a new member of the jun proto-oncogene family. *EMBO J.* **8**:1433–1439.
- Hofer, F., S. Fields, C. Schneider, and G. S. Martin. 1994. Activated ras interacts with the ral guanine nucleotide dissociation stimulator. *Proc. Natl. Acad. Sci. USA* **91**:11089–11093.
- Hu, E., E. Mueller, S. Oliviero, V. E. Papaioannou, R. Johnson, and B. M. Spiegelman. 1994. Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. *EMBO J.* **13**:3094–3103.
- Hu, Q., A. Klippel, A. J. Mustin, W. J. Fantl, and L. T. Williams. 1995. Ras dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. *Science* **268**:100–102.
- Ivashkiv, L. B., H.-C. Liou, C. J. Kara, W. W. Lamph, I. M. Verma, and L. H. Glimcher. 1990. mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. *Mol. Cell. Biol.* **10**:1609–1621.
- Jat, P. S., C. L. Cepko, R. C. Mulligan, and P. A. Sharp. 1986. Recombinant retroviruses encoding simian virus large T antigen and polyoma virus large and middle T antigens. *Mol. Cell. Biol.* **6**:1204–1217.
- Johnson, R. S., B. van Lingen, V. E. Papaioannou, and B. M. Spiegelman. 1993. A null mutation at the c-Jun locus causes embryonic lethality and retarded cell growth in culture. *Genes Dev.* **7**:1309–1317.
- Jonat, G., H. J. Rahmsdorf, K.-K. Park, A. C. B. Cato, S. Gebel, H. Ponta, and P. Herrlich. 1990. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos-Jun) by glucocorticoid hormone. *Cell* **62**:1189–1204.
- Kikuchi, A., S. D. Demo, Z.-H. Ye, Y.-W. Chen, and L. T. Williams. 1994. ralGDS family members interact with the effector loop of ras p21. *Mol. Cell. Biol.* **14**:7483–7491.
- Kyriakis, J. M., P. Banerjee, P. Nikkolokaki, T. Dai, E. A. Rubie, M. F. Ahmad, J. Avruch, and J. R. Woodgett. 1994. The stress-activated protein kinase subfamily of c-jun kinases. *Nature (London)* **369**:156–160.
- Lamph, W. W., P. Wamsley, P. Sassone-Corsi, and I. M. Verma. 1988. Induction of proto-oncogene Jun/AP-1 by serum and TPA. *Nature (London)* **334**:629–631.
- Lane, D. P., and L. V. Crawford. 1979. T-antigen is bound to host proteins in SV40-transformed cells. *Nature (London)* **278**:261–263.
- Lloyd, A., N. Yancheva, and B. Wasylyk. 1991. Transformation suppressor activity of a Jun transcription factor lacking its activation domain. *Nature (London)* **352**:635–638.
- Macgregor, P. F., C. Abate, and T. Curran. 1990. Direct cloning of leucine zipper proteins: Jun binds cooperatively to the CRE with CRE-BP1. *Oncogene* **5**:451–458.
- Mansour, S. J., W. T. Matten, A. S. Hermann, J. M. Candia, S. Rong, K. Fukasawa, G. F. Van de Woude, and N. G. Ahn. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase. *Science* **265**:966–970.
- Marais, R., J. Wynne, and R. Treisman. 1993. The SRF accessory protein Elk-1 contains a growth factor regulated transcriptional activation domain. *Cell* **73**:381–393.
- Matrisian, L. M., P. Leroy, C. Ruhlmann, M.-C. Gesnel, and R. Breathnach. 1986. Isolation of the oncogene and epidermal growth factor-induced transgene: complex control in rat fibroblasts. *Mol. Cell. Biol.* **6**:1679–1686.
- Minden, A., A. Lin, M. McMahon, C. Lange-Carter, B. Derijard, R. J. Davis, G. L. Johnson, and M. Karin. 1994. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. *Science* **266**:1719–1723.
- Morganstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and complementary helper-free packaging cell line. *Nucleic Acids Res.* **18**:3587–3596.
- Petit, C. A., M. Gardes, and J. Feunteun. 1983. Immortalization of rodent embryo fibroblasts by SV40 is maintained by the A gene. *Virology* **127**:74–82.
- Pfarr, C. M., F. Mehta, G. Spyrou, D. Lallemand, S. Carillo, and M. Yaniv.

1994. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. *Cell* **76**:747–760.
43. **Pulverer, B. J., J. M. Kyriakis, J. Avruch, E. Nikolakaki, and J. R. Woodgett.** 1991. Phosphorylation of c-jun mediated by MAP kinases. *Nature (London)* **353**:670–674.
  44. **Qiu, R. G., J. Chen, D. Kirn, F. McCormick, and M. Symons.** 1995. An essential role for rac in ras transformation. *Nature (London)* **374**:457–459.
  45. **Ridley, A. J., H. F. Paterson, C. L. Johnston, D. Diekmann, and A. Hall.** 1992. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. *Cell* **70**:401–410.
  46. **Rodriguez-Viciana, P., P. H. Warne, R. Dhand, B. Vanhaesbroek, I. Gout, M. J. Fry, M. D. Waterfield, and J. Downward.** 1994. Phosphatidylinositol-3-OH kinase as a direct target of ras. *Nature (London)* **370**:527–532.
  47. **Ryseck, R. P., S. I. Hirai, M. Yaniv, and R. Bravo.** 1988. Transcriptional induction of c-jun during the G0/G1 transition in mammalian cells. *Nature (London)* **334**:535–537.
  48. **Saez, E., S. E. Rutberg, E. Mueller, H. Oppenheim, J. Smoluk, S. H. Yuspa, and B. M. Spiegelman.** 1995. c-fos is required for malignant progression of skin tumors. *Cell* **82**:721–732.
  49. **Schule, R., P. Rangarajan, S. Kliewer, L. J. Ransone, J. Bolado, N. Yang, I. M. Verma, and R. M. Evans.** 1990. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. *Cell* **62**:1217–1226.
  50. **Smeal, T., B. Binetruy, D. Mercola, B. A. Brover, G. Heidecker, U. R. Rapp, and M. Karin.** 1991. Oncogenic and transcriptional cooperation with Ha-ras requires phosphorylation of c-jun on serines 63 and 73. *Nature (London)* **354**:494–496.
  51. **Spaargaren, M., and J. R. Bischoff.** 1994. Identification of the guanine nucleotide dissociation stimulator for ral as a putative effector molecule of R-ras, N-ras, K-ras, and Rap. *Proc. Natl. Acad. Sci. USA* **91**:12609–12613.
  52. **Ullman, K. S., J. P. Northrop, A. Admon, and G. R. Crabtree.** 1993. Jun family members are controlled by a calcium-regulated, cyclosporin A-sensitive signaling pathway in activated T lymphocytes. *Genes Dev.* **7**:188–196.
  53. **Van Aelst, L., M. Barr, S. Marcus, A. Polverino, and M. Wigler.** 1993. Complex formation between ras and raf and other protein kinases. *Proc. Natl. Acad. Sci. USA* **90**:6213–6217.
  54. **Vojtek, A. B., S. M. Hollenberg, and J. A. Cooper.** 1993. Mammalian ras interacts directly with the serine/threonine kinase Raf. *Cell* **74**:205–214.
  55. **Warne, P. H., P. Rodriguez-Viciana, and J. Downward.** 1993. Direct interaction of ras and the amino-terminal region of Raf-1 in vitro. *Nature (London)* **364**:352–355.
  56. **White, M. A., C. Nicolette, A. Minden, A. Polverino, L. Van Aelst, M. Karin, and M. Wigler.** 1995. Multiple ras functions can contribute to mammalian cell transformation. *Cell* **80**:533–541.
  57. **Wisdom, R., and R. Johnson.** Unpublished data.
  58. **Wisdom, R., J. Yen, D. Rashid, and I. M. Verma.** 1992. Transformation by FosB requires a trans-activation domain missing in FosB2 that can be substituted by heterologous activation domains. *Genes Dev.* **6**:667–675.
  59. **Yang-Yen, H.-F., J.-C. Chambard, Y.-L. Sun, T. Smeal, T. J. Schmidt, J. Drouin, and M. Karin.** 1990. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. *Cell* **62**:1205–1215.
  60. **Zhang, X., J. Settleman, J. Kyriakis, E. Takeuchi-Suzuki, S. J. Elledge, M. S. Marshall, J. T. Bruder, U. R. Rapp, and J. Avruch.** 1993. Normal and oncogenic p21<sup>ras</sup> proteins bind to the amino-terminal regulatory domain of c-Raf-1. *Nature (London)* **364**:308–313.

**C****+/+****+/+ ras****-/-****-/- ras**